Filing Flows › Health Care › QHSLab (USAQ)
QHSLab (USAQ) earnings and revenue breakdown
Latest: Q2 2026 · 10-Q filed Aug 12, 2026 · QHSLab (USAQ) Q2 2026 earnings results →
Q2 2026 Revenue up 40% year over year to $847K · 4¢ of every $1 of revenue kept as net profit · operating margin 5.3%
QHSLab made $847K in Q2 2026 (+40% Y/Y): Integrated Service Program $491K, Allergy Diagnostic Kit Sales $196K, Immunotherapy Treatment Sales $94K. Operating margin 5.3%, net earnings $38K. See where every dollar goes — costs, profit and cash — as a Sankey from the 10-Q filed Aug 12, 2026.
Drawing the Sankey…
Open the interactive Sankey → click any line for what the company wrote about it, compare Y/Y and Q/Q, export as PNG or PDF
What changed this quarter
Revenue was $847K in Q2 2026, up 40% year over year and up 16% from the previous quarter. Integrated Service Program was the largest line at 58% of revenue. Integrated Service Program added $228K year over year (up 86%), 94% of the total change. Subscription Revenue declined 28%.
Gross margin was 69.6%, up 3.7 points from Q2 2025. Operating profit was $45K, a 5.3% margin (up 3.4 points year over year). Of the extra revenue versus Q2 2025, 14% reached operating profit, above the 2% margin then. Operating expenses grew 41% against revenue growth of 40%. The fastest-growing cost line was General & admin (+70%). Net earnings were $38K. The effective tax rate was 0.0%.
Operating cash flow was −$8K. Non-cash charges added back $18K of depreciation and amortization. Working capital and other items used $64K.
Quarterly history
| Quarter | Form | Filed | Revenue | Y/Y | Op. margin | Net earnings | Op. cash flow |
|---|---|---|---|---|---|---|---|
| Q2 2026 | 10-Q | Aug 12, 2026 | $847K | +40% | 5.3% | $38K | −$8K |
| Q1 2026 | 10-Q | May 14, 2026 | $729K | +13% | -13.0% | −$104K | −$200K |
| Q4 2025 | 10-K | Mar 30, 2026 | $704K | +12% | 5.0% | $557K | $98K |
| Q3 2025 | 10-Q | Nov 13, 2025 | $737K | +35% | 13.1% | $33K | $3K |
| Q2 2025 | 10-Q | Aug 14, 2025 | $605K | +28% | 1.9% | −$53K | $127K |
| Q1 2025 | 10-Q | May 14, 2025 | $645K | +32% | -1.9% | −$80K | −$50K |
| Q4 2024 | 10-K | Mar 28, 2025 | $626K | +99% | 11.7% | −$288K | $55K |
Charts
Interactive views
The same charts as the app — open one to draw it.
💵Where each $1 goesinteractive
Loading the interactive chart…
🌏Named in Asian annual reportsinteractive
Loading the interactive chart…
🔄Rotation against the market and its industry (RRG)interactive
Loading the interactive chart…
🔍Earnings qualityinteractive
Loading the interactive chart…
⚖️Fair value by methodinteractive
Loading the interactive chart…
🔭Outlook & guidanceinteractive
Loading the interactive chart…
📈Investments: gains and what it boughtinteractive
Loading the interactive chart…
🏭Its industry’s money flow (input-output)interactive
Loading the interactive chart…
About QHSLab
QHSLab, Inc. is a digital health company focused on enabling independent primary care practices to identify, document, and manage underdiagnosed and undertreated behavioral health conditions (behavioral vital signs) through workflow-integrated digital screening and non-face-to-face follow-up care. Our platform is designed to support population-based screening, patient education, and follow-up care management activities that occur outside of traditional in-office encounters. We generate revenue primarily through recurring per-patient, per-month fees paid by participating medical practices for access to and use of our digital platform and associated services. The platform supports reimbursable clinical activities, including digital assessments, asynchronous interactions, and care management services, which may be billed by practices in accordance with applicable payer rules.
In its own words, from its 10-K, filed Mar 30, 2026.
QHSLab against its Surgical & Medical Instruments & Apparatus peers
The largest companies of the same SEC industry, each at its latest quarter. Revenue growth: +40% against the peers' median +5%. Operating margin: 5.3% against the peers' median 13.3%.
| Company | Quarter | Revenue | Y/Y | Op. margin |
|---|---|---|---|---|
| USAQ QHSLab | Q2 2026 | $847K | +40% | 5.3% |
| MDLN Medline | Q3 2026 | $7.9B | +10% | 6.4% |
| MMM 3M | Q3 2026 | $6.6B | +1% | 23.7% |
| SYK Stryker | Q3 2026 | $6.5B | +8% | 15.9% |
| BSX Boston Scientific | Q3 2026 | $5.1B | +1% | 16.1% |
| BDX Becton Dickinson | Q3 FY26 | $5.0B | +5% | 13.3% |
| BAX Baxter International | Q3 2026 | $3.0B | +5% | 7.6% |
| SOLV Solventum | Q3 2026 | $1.9B | -7% | 3.5% |
| RMD ResMed | Q1 FY27 | $1.4B | +6% | 32.0% |
Source: QHSLab 10-Q on SEC EDGAR · CIK 856984 · Surgical & Medical Instruments & Apparatus
More on USAQ
History
Every quarter: Q2 2026 results · Q1 2026 results · Q4 2025 results · Q3 2025 results · Q2 2025 results · Q1 2025 results · Q4 2024 results